Financial Performance - The company's basic earnings per share decreased by 20.47% to 3.0279 yuan in 2024 from 3.8073 yuan in 2023 [1] - Net profit fell by 21.61% to 3.99 billion yuan in 2024 compared to 5.09 billion yuan in 2023 [1] - Operating revenue declined by 9.19% to 14.32 billion yuan in 2024 from 15.77 billion yuan in 2023 [1] - The return on equity decreased by 23.87% to 11.64% in 2024 from 15.29% in 2023 [1] - The net asset per share slightly decreased by 0.65% to 25.93 yuan in 2024 from 26.1 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 49.22 million shares, accounting for 40.86% of the circulating shares, with a decrease of 7.2829 million shares compared to the previous period [2] - The largest shareholder, Aokang Group Co., Ltd., holds 16.3055 million shares, representing 13.53% of the total share capital, with no change [3] - Jinan Kangyue Qiming Investment Partnership reduced its holdings by 280,300 shares, now holding 9.7197 million shares, which is 8.07% of the total [3] - New entrants among the top shareholders include a securities investment fund holding 8.079 million shares, accounting for 6.70% [3] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share (including tax) [4]

美康生物：2024年营业收入17.42亿元，同比下降7.61%。归属于上市公司股东的净利润2.58亿元，同比 增长0.56%。 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [4][20] Core Views - The company's product business revenue grew by 42% year-on-year, but net profit is under short-term pressure, with a projected revenue of 297 million yuan (+22.3%) and a net profit of 21 million yuan (-61.0%) for 2024 [1][7] - The decline in net profit is attributed to the operational costs associated with the new CDMO biopharmaceutical commercialization production platform and impairment losses of 10.03 million yuan [1][7] - The company has a strong pipeline with 247 confirmed drug development lines using its cell culture products, an increase of 77 from the previous year [2][16] Financial Performance - For 2024, the company achieved product sales of 244 million yuan (+42.0%) with a gross margin of 70.0% [1][7] - CDMO services generated revenue of 52.56 million yuan (-25.7%), primarily due to uncertainties in the biopharmaceutical industry affecting client financing [1][7] - The quarterly sales for 2024 are projected to improve sequentially: 8.05 million yuan in Q1, 11.62 million yuan in Q2, 15.84 million yuan in Q3, and 17.05 million yuan in Q4 [1][7] Regional Performance - The company's overseas business showed strong growth, with foreign revenue increasing by 144.0% compared to the previous year [2][7] Earnings Forecast - The earnings forecast has been adjusted, with expected net profits of 78 million yuan and 112 million yuan for 2025 and 2026, respectively, and a new projection of 153 million yuan for 2027 [2][20] - The current price-to-earnings (PE) ratios are projected at 58x for 2025, 41x for 2026, and 30x for 2027 [2][20] Key Financial Metrics - The company reported a net profit margin of 1.0% for 2024, with a significant increase expected in subsequent years [3][23] - The projected revenue growth rates are 27.1% for 2025 and 21.3% for 2026, indicating a recovery trend [3][23]

Financial Performance - In 2024, the company reported operating revenue of 80.80 million yuan, a year-on-year decrease of 39.96% [1] - The net profit attributable to shareholders was -93.50 million yuan, compared to -70.99 million yuan in the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -106 million yuan, down from -72.57 million yuan year-on-year [1] - The net cash flow from operating activities was -131 million yuan, compared to 80.90 million yuan in the previous year [1] - For Q1 2025, the company achieved operating revenue of 3.46 million yuan, a decrease of 30.97% year-on-year [1] - The net profit attributable to shareholders for Q1 2025 was -17.58 million yuan, compared to -21.49 million yuan in the same period last year [1] - The net cash flow from operating activities for Q1 2025 was -42.06 million yuan, compared to -45.35 million yuan in the previous year [1] Dividend Policy - The company plans not to distribute profits for the 2024 fiscal year, with no cash dividends, capital reserve transfers, or stock bonuses [1] IPO and Fundraising - The company was listed on the Sci-Tech Innovation Board on August 2, 2021, with an initial public offering of 22 million shares at a price of 55.18 yuan per share [2] - The total amount raised from the IPO was 1.214 billion yuan, with a net amount of 1.136 billion yuan, which was 464 million yuan less than the originally planned net amount [2] - The company initially aimed to raise 1.6 billion yuan for various projects, including the construction of a new vaccine production facility and research and development [2] - The total issuance costs for the IPO were 78.28 million yuan, with the underwriter, CITIC Securities, receiving 64.34 million yuan in fees [2]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1400 | -0.1700 | 17.65 | 0.3000 | | 每股净资产（元） | 10.23 | 10.95 | -6.58 | 17 | | 每股公积金(元) | 9.06 | 9.06 | 0 | 13.08 | | 每股未分配利润(元) | -0.05 | 0.68 | -107.35 | 2.62 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.03 | 0.05 | -40 | 1.06 | | 净利润(亿元) | -0.18 | -0.21 | 14.29 | 0.36 | | 净资产收益率(%) | -1.39 | -1.58 | 12.03 | 2.46 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 9429.17万股，累计占流通股比： 76.5 ...

Core Points - The company reported a revenue of 80.8027 million yuan for 2024, representing a year-on-year decline of 39.96% [1] - The net loss attributable to shareholders was 93.5028 million yuan, compared to a net loss of 70.9903 million yuan in the same period last year [1] - The basic earnings per share were -0.76 yuan per share [1] - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves, with the remaining undistributed profits carried forward to the next year [1]

奥浦迈（688293.SH） 培养基持续高增，海外市场表现靓丽，项目数增加巩固竞争优势 奥浦迈发布 2024 年年度报告。2024 年实现营业收入 2.97 亿元，同比增长 22.26%；归母净利润 2105 万元，同比下滑 61.04%；扣非后归母净利润 659 万元，同比下滑 81.03%。分季度看，2024Q4 实现营业收入 8139 万元，同比 增长 13.93%；归母净利润-618 万元，同比下滑 156.95%；扣非后归母净利 润-1049 万元，同比下滑 446.72%。 观点：收入端稳健增长，固定成本增加、减值计提等多因素影响利润端增速不 及收入端。培养基延续高增态势，海外市场增长势头强劲，CDMO 平台产能 爬坡有望带动服务亏损收窄。海内外客户持续开拓，培养基客户数量及管线规 模增长显著，持续巩固领先竞争优势。 2024 年收入端稳健增长，多因素影响利润端增速不及收入端。行业融资环境 紧缩的背景下，公司收入端高速增长，展现了较强的经营韧性。利润端增速不 及收入端系多种因素影响：1）募投项目"奥浦迈 CDMO 生物药商业化生产平 台"投入运营，相关固定成本增加较多；2）计提长期资产减值损失 1 ...

Core Insights - WanTai Bio's 2024 annual report reveals significant declines in revenue and net profit, marking the lowest figures since its listing five years ago and the lowest net profit in nearly a decade [1][5]. Financial Performance - In 2024, WanTai Bio reported revenue of 2.245 billion RMB, a decrease of 59.25% compared to 5.511 billion RMB in 2023 [2][5]. - The net profit attributable to shareholders was 106 million RMB, down 91.49% from 1.248 billion RMB in the previous year [2][5]. - The net loss after excluding non-recurring items was 186 million RMB, a decline of 117.29% from a profit of 1.078 billion RMB in 2023 [2][5]. - The net cash flow from operating activities was 355 million RMB, a decrease of 76.91% from 1.538 billion RMB in 2023 [2]. Segment Performance - Vaccine revenue fell to 606 million RMB, a drop of 84.69%, with a gross margin of 70.43%, down 21.17% year-on-year [5][6]. - Reagent revenue increased by 7.66% to 1.433 billion RMB, with a gross margin of 75.46%, down 1.11% [5][6]. - Instrument revenue decreased by 36.35% to 38.8 million RMB, with a gross margin of -310.56%, down 154.06% [5][6]. - Active ingredient revenue was 22.8 million RMB, down 13.02%, with a gross margin of 90.19%, up 5.73% [5][6]. - Agency product revenue slightly decreased by 1.02% to 113 million RMB, with a gross margin of 55.83%, up 10.78% [5][6]. Ownership and Control - The actual controller of WanTai Bio is Zhong Shanshan, who, along with his company Yangshengtang, holds 73.49% of the shares [6].

Core Insights - WanTai BioPharma (SH603392) reported a significant decline in revenue and net profit for the year 2024, with revenue at 2.245 billion RMB, down 59.25% year-on-year, and net profit at 106 million RMB, down 91.49% [1][2][5] Financial Performance - Revenue for 2024 was 2.245 billion RMB, compared to 5.511 billion RMB in 2023, marking a 59.25% decrease [2] - Net profit attributable to shareholders was 106 million RMB, down from 1.248 billion RMB in 2023, a decline of 91.49% [1][2] - The net loss after excluding non-recurring items was 186 million RMB, a decrease of 117.29% compared to a profit of 1.078 billion RMB in 2023 [1][2] Segment Performance - Vaccine revenue fell to 606 million RMB, a decrease of 84.69%, with a gross margin of 70.43%, down 21.17% from the previous year [5][6] - Reagent revenue increased to 1.433 billion RMB, up 7.66%, with a gross margin of 75.46%, down 1.11% [5][6] - Instrument revenue was 38.78 million RMB, down 36.35%, with a gross margin of -310.56% [5][6] - Active ingredient revenue was 22.76 million RMB, down 13.02%, with a gross margin of 90.19%, up 5.73% [5][6] - Agency product revenue was 113 million RMB, down 1.02%, with a gross margin of 55.83%, up 10.78% [5][6] Management Compensation - In 2024, the chairman's salary was 1.8 million RMB, lower than the general manager's salary of 2.281 million RMB and the deputy general manager's salary of 2.073 million RMB [6][8] - The chairman's salary has decreased over the past two years, reflecting a trend of reduced compensation [8]

万泰生物首次发行费用为6365.19万元，其中，国金证券获得承销及保荐费用4346.00万元。 2021年，万泰生物10送4股派2.50元(含税)，2022年公司10送2股转2.5股派2元(含税)，2023年10转4股派10元(含税)。 万泰生物于2020年7月7日披露的非公开发行A股股票发行情况报告书显示，公司此次非公开发行股票的数量为25,862,705股，发行 价格为135.33元/股，实际募集资金总额为3,499,999,867.65元，减除相关发行费用39,844,153.48元，募集资金净额为 3,460,155,714.17元。 | | | | | 分红 | | | | --- | --- | --- | --- | --- | --- | --- | | 公告日期 | | 分红方案(每10股) | | 进度 | 除权除息日 | 股权登记日 | | | 送股(股) | 转增(股) 派息(税前)(元) | | | | | | 2024-05-28 | 0 | 0 | 3.2 | 实施 | 2024-06-03 | 2024-05-31 | | 2023-05-30 | 0 | র্ব | 10 | ...